Dec 5, 2024, 16:26 | Insight

Nitin Jain: Update on Pirto Ven and Obin triplet in firstline CLL

Nitin Jain, Professor of Medicine at The University of Texas MD Anderson Cancer Center, shared…

Dec 5, 2024, 16:20 | Insight

ASH24 studies from MD Anderson presented by Jayastu Senapati

Jayastu Senapati, Assistant Professor of Leukemia at MD Anderson Cancer Center, shared on X: “ASH24…

Nov 24, 2024, 05:47 | Blog

Vivek Subbiah: Honored to host a JAMA Oncology podcast with Hagop Kantarjian

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, posted on…

Oct 22, 2024, 23:27 | Blog

Naveen Pemmaraju: Proud to highlight our world-class Leukemia Fellowship

Naveen Pemmaraju Director of BPDCN Program at the University of Texas MD Anderson Cancer Center,…

Oct 17, 2024, 16:33 | Insight

Vincent Rajkumar: The Disadvantages of Medicare Advantage

Vincent Rajkumar shared a post on X: "The Disadvantages of Medicare Advantage. Please read our paper…

Oct 8, 2024, 12:36 | Blog

Vincent Rajkumar: We as doctors should take cost into account when prescribing tests and treatments

Vincent Rajkumar, Editor-in-Chief, Blood Cancer Journal, shared a post on X: "We as doctors should…

Oct 1, 2024, 11:05 | Blog,Insight

Mohamed Benlazar: General approach to patients with AML

Mohamed Benlazar, Professor of Hematology at Sidi Bel Abbès University Hospital, shared a post on…

Sep 26, 2024, 15:39 | Insight

Article of the Week, Suggested by the BPDCN International Registry

Immune Oncology Research Institute shared a post on LinkedIn: "Article of the Week Suggested by the…

Sep 21, 2024, 14:48 | Career

Naveen Pemmaraju receives the IACH 2024 Special Achievement Award

The 7th Annual Meeting of the International Academy for Clinical Hematology (IACH), featuring the COMydAL,…

Sep 11, 2024, 09:16 | Insight

Naveen Pemmaraju: Pivekimab sunirine in relapsed or refractory acute myeloid leukaemia

Naveen Pemmaraju shared a post on X about a recent paper by Naval Daver et…

Sep 11, 2024, 06:31 | Career

Phillip Scheinberg: Honored to step into the role of President of the Society of Hematologic Oncology

Phillip Scheinberg is the Head of Hematology at the Oncology and Hematology Center of BP…

Aug 26, 2024, 21:22 | Blog

Vincent Rajkumar: Why are prescription drug prices far higher in the US than other developed countries

Vincent Rajkumar shared a post on X: “Why are prescription drug prices are far higher…

Aug 22, 2024, 13:46 | Insight

Hagop Kantarjian: The latest advancements and progress in treating AML

Hagop Kantarjian shared a post on X: “Recording now available: The latest advancements and progress…

Aug 19, 2024, 10:38 | Insight

Hagop Kantarjian: All you need to know about the latest JAK inhibitor to be approved for myelofibrosis

Hagop Kantarjian shared a post on X about a recent paper by Prithviraj Bose published…

Aug 10, 2024, 12:57 | Insight

MD Anderson Research Highlights

Featuring cell biology insights, new targets to prevent dysphagia, improved treatments for advanced cancers and…

Aug 9, 2024, 12:55 | Insight

An updated analysis of ponatinib and blinatumomab combination in Ph+ acute lymphoblastic leukemia

MD Anderson Cancer Center shared a post on X: "Dr. Hagop Kantarjian shares an updated…

Jul 30, 2024, 06:08 | Insight

Mark Geyer: Practice-changing ECOG 1910 trial led by Mark Litzow

Mark Geyer, Assistant Professor Of Medicine at Weill Cornell Medicine, shared on X about a…

Jul 25, 2024, 13:59 | Blog

Oncoinfluencers to Follow on Social Media: Dr. Hagop Kantarjian

We are excited to feature Dr. Hagop Kantarjian, a distinguished figure in Hematology/Oncology, as our…

Jul 23, 2024, 22:30 | Blog

Hagop Kantarjian: The simultaneous combination of ponatinib and blinatumomab highly effective

Hagop Kantarjian shared on X: "The simultaneous combination of ponatinib and blinatumomab highly effective: MRD-negativity rate…

Jul 23, 2024, 06:05 | Blog

Talha Badar: The role of allogeneic stem cell transplantation in Ph+ve ALL

Talha Badar shared on X: "The role of allogeneic stem cell transplantation in Ph+ve ALL? Outcome…

Jul 22, 2024, 13:23 | Blog

Naveen Pemmaraju: CK0801 in Treatment of Bone Marrow Failure Syndromes

Naveen Pemmaraju posted on X about recent paper by Tapan M. Kadia et al., commenting:…

Jul 20, 2024, 14:27 | Insight

Naveen Pemmaraju: Important paper on AML and Hyperleukocytosis

Naveen Pemmaraju shared a post about a paper titled "Outcomes of Patients With Newly Diagnosed…

Jul 19, 2024, 13:27 | Insight

Fadi Haddad: Hyperleukocytosis in Acute myeloid leukemia

Fadi Haddad, Assistant Professor at Leukemia Department at MD Anderson Cancer Center, shared a post…

Jul 14, 2024, 21:36 | Blog

Jayastu Senapati: Hagop Kantarjian delivers the keynote address on CML at the Annual AML/ALL US Focus meeting

Jayastu Senapati shared a post on X: ''Hagop Kantarjian delivering the keynote address on CML…

Jun 29, 2024, 16:57 | Insight

MD Anderson Research Highlights: EHA 2024 Special Edition

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in…

Jun 24, 2024, 13:16 | Insight

Hagop Kantarjian: NPM1-mutant myeloid neoplasms should be treated with AML-type treatment

Hagop Kantarjian shared on X: . "NPM1-mutant myeloid…

Jun 21, 2024, 07:08 | Insight

Hagop Kantarjian: New encouraging secondary HLH treatment by Abhishek Maiti et al.

Hagop Kantarjian shared a post on X: "New encouraging secondary HLH treatment - Abhishek Maiti."…

Jun 19, 2024, 23:09 | Blog

Wei Ying Jen: Very grateful to be standing on the shoulders of giants

Wei Ying Jen, Haematologist and Leukemia Doctor at MD Anderson Cancer Center, shared on X:…

Jun 17, 2024, 07:05 | Societies

15 Posts You Should Not Miss From EHA 2024!

The European Hematology Association (EHA) Hybrid Congress or EHA2024 will took place in Madrid, Spain…

Jun 15, 2024, 13:31 | Insight

Hagop Kantarjian: Chemo-free regimens are highly effective in Ph+ALL

Hagop Kantarjian shared on X/Twitter: "Chemo-free regimens (TKIs-blinatumomab) highly effective in Ph+ALL; may replace intensive chemotherapy…

Jun 9, 2024, 14:59 | Opinion

Naveen Pemmaraju: Fantastic evening at Leukemia Fellow Graduation

Naveen Pemmaraju shared a post on X: "Fantastic evening Leukemia Fellow Graduation. Nice speeches from Hagop…

May 25, 2024, 09:12 | Insight

Sankalp Arora: Excited to be presenting longterm follow up results of AZA + RUX in patients with myelofibrosis at ASCO24

Sankalp Arora, Heme/Onc fellow at MD Anderson Cancer Center, shared on X/Twitter: "The ASCO24 countdown begins!…

May 19, 2024, 10:00 | Blog

Hagop Kantarjian: A comprehensive review of ponatinib in CML and Ph+ ALL

Hagop Kantarjian, Leukaemia professor and Chair at MD Anderson Cancer Center, shared on X: "A comprehensive…

May 15, 2024, 14:47 | Drugs

Hagop Kantarjian: New research is expanding inotuzumab use into frontline, for MRD+, and in combination with blinatumomab

Nicholas Short, Associate Professor at the Department of Leukemia at MD Anderson Cancer Center, shared…

May 12, 2024, 07:56 | Dialogues

OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan

Join us for an exciting new episode of “OncoInfluencers”, hosted by Dr. Gevorg Tamamyan. In this episode, we…

Apr 26, 2024, 08:09 | Blog

Hagop Kantarjian: The results of the first clinical trial to explore activin receptor ligand traps of drugs in MF

Hagop Kantarjian, Leukaemia professor and Chair at MD Anderson Cancer Center, shared on X: ''Activin receptor…

Apr 21, 2024, 21:27 | Drugs

Hagop Kantarjian: We review the evidence leading to Tagraxofusp approval as first in class CD123-directed drug which has changed the field of BPDCN

Hagop Kantarjian, Leukaemia professor and Chair at MD Anderson Cancer Center, shared on X: “Tazgraxofusp is…

Apr 20, 2024, 07:03 | Drugs

Hagop Kantarjian: Dasatinib and Venetoclax is safe and effective in newly diagnosed CML in CP

Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas…

Apr 5, 2024, 08:22 | Insight

Hagop Kantarjian: Low-dose azacitidine plus venetoclax - in patients with AML unable to complete standard consolidation strategies

Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas…

Mar 10, 2024, 20:49 | Insight

Hagop Kantarjian: In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia

Hagop Kantarjian, a Professor and Chair of the Department of Leukemia at The University…

Mar 4, 2024, 10:16 | Blog

Hagop Kantarjian: Gamma delta T cells, a novel immunotherapy for AML

Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas MD…

Feb 21, 2024, 20:45 | Blog

Peter Pisters: Delighted to drop by MD Anderson Cancer Center's Leukemia faculty to discuss the exceptional breakthroughs over the years

Peter Pisters, President at MD Anderson Cancer Center, shared on LinkedIn: “Delighted to drop by…

Feb 18, 2024, 15:51 | Blog

Hagop Kantarjian: In this Ph1b trial, single agent SQ blinatumomab resulted in a high MRD-negative complete remission rate

Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer…

Feb 8, 2024, 05:16 | Insight

Hagop Kantarjian: A new standard of care in newly diagnosed older FLT3-mutated AML

Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer…

Jan 18, 2024, 11:27 | Insight

Hagop Kantarjian: Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated relapsed/refractory Acute Lymphoblastic Leukemia

Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson…

Jan 16, 2024, 11:37 | Insight

Jayastu Senapati: Check out our SOHO State of the Art Review on Acute Lymphoblastic Leukemia

Jayastu Senapati, Assistant Professor at the Department of Leukemia at MD Anderson Cancer Center, shared…

Jan 10, 2024, 12:42 | Blog

Danielle Hammond: Proof of concept and breaks the yoke of the infusion center

Danielle Hammond, Assistant Professor at the Department of Leukemia at MD Anderson Cancer Center, shared…

Jan 9, 2024, 13:10 | Blog

Hagop Kantarjian: Updates on the management of Ph-positive ALL

Hagop Kantarjian, Chair of MD Anderson Cancer Center, shared on X/Twitter: “Updates on the management…

Dec 23, 2023, 17:05 | Blog

Hagop Kantarjian: Traditional Medicare or Medicare Advantage?

Hagop Kantarjian, Chair of MD Anderson Cancer Center, shared on X/Twitter: "Traditional Medicare or Medicare…

Nov 10, 2023, 18:32 | Blog

Gevorg Tamamyan: Such an honor to be part of the great Society of Hematologic Oncology and to be the Ambassador of the Society to Armenia

Gevorg Tamamyan, the Editor-in-Chief of OncoDaily and the Head of the Pediatric Cancer and Blood…

Nov 6, 2023, 03:36 | Drugs

Hagop Kantarjian: Inotuzumab is safe and effective for the eradication of MRD in patients with B-cell ALL, with a MRD negativity rate of 69%

Hagop Kantarjian, Chair of MD Anderson Cancer Center, shared a post on Twitter: Inotuzumab is…

Nov 4, 2023, 16:12 | Drugs

Vincent Rajkumar: How I treat newly diagnosed myeloma

Vincent Rajkumar, Editor-in-Chief of the Blood Cancer Journal, shared on Twitter: "How I treat newly…

Sep 27, 2023, 18:06 | Drugs

Hagop Kantarjian: Combination of venetoclax and hypomethylating agent provides high rates of durable remission and overall survival in both newly diagnosed and R/R IDH1/2-mutated Acute Myeloid Leukemia.

Sep 12, 2023, 17:40 | Blog

11 Tweets from SOHO23 not to miss.

The Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) took place at…

Sep 9, 2023, 20:34 | Blog

Jorge Cortes: It is an honor to receive this award named after a giant in leukemia research and a great mentor to me by another giant and mentor Hagop Kantarjian at the Society of Hematologic Oncology (SOHO).

Sep 6, 2023, 17:14 | Positive

Dr. Hagop Kantarjian received Emil J Freireich Distinguished Pioneer Award at the SOHO 2023

"Legendary leukemia doctor and scientist Dr. Hagop Kantarjian received Emil J Freireich Distinguished Pioneer Award…

Sep 1, 2023, 18:38 | Drugs

Hagop Kantarjian: Now out in American Journal of Hematology reporting Ph II trial of CLIA +/- Sorafenib in newly diagnosed AML.

Hagop Kantarjian, Department Chair, Department of Leukemia, Division of Cancer Medicine at MD Anderson Cancer…

Aug 31, 2023, 19:04 | Insight

Naveen Pemmaraju: Ph2 CLIA with or without sorafenib for upfront AML therapy.

Naveen Pemmaraju, the Executive Director of Cancer Medicine at the MD Anderson Cancer Center, recently…

Aug 31, 2023, 18:45 | Career

Naveen Pemmaraju: Wonderful MDACC MPN team farewell luncheon today in honor of Mary Ann Richie, our leader for MPN research RN group, as she retires from MD Anderson Cancer Center!

Aug 20, 2023, 16:32 | Blog

Hagop Kantarjian: Join us in welcoming Alexandre Bazinet, MDCM, MSc to our MD Anderson Cancer Center Leukemia Faculty!

Hagop Kantarjian, Leukemia Professor and Chair at MD Anderson Cancer Center, shared on Twitter: "Join…

Jul 22, 2023, 17:56 | Drugs

High response rates in poor-risk population - Hagop Kantarjian

Our study of aza + ven + pevonedistat NEDD8-activating enzyme inhibitor in secondary AML &…

Jul 18, 2023, 19:39 | Drugs

Venetoclax helps to eliminate the adverse prognostic impact of splicing factor mutations in pts with newly diagnosed AML

Quoting Hagop Kantarjian on Twitter, "MD Anderson Cancer Center's Leukemia researchers identify the use of venetoclax…

Jul 12, 2023, 17:40 | Blog

Wonderful AML-ALL US Focus annual conference in La Jolla last weekend - Ryan Fitzpatrick

Wonderful AML-ALL US Focus annual conference in La Jolla last weekend. Co-chaired by Drs Naval…

Jul 8, 2023, 12:23 | Stories

Dr. Hagop Kantarjian isn’t just chair of Leukemia at MD Anderson - MD Anderson Cancer Center

Our Dr. Hagop Kantarjian isn’t just chair of Leukemia at MD Anderson; he’s also a…

Jul 5, 2023, 05:38 | Blog

15 years ago exactly to the day, I arrived in Houston TX - Naveen Pemmaraju

So grateful to MD Anderson Cancer Center !! 15 years ago exactly to the day, I arrived…

Jun 16, 2023, 19:38 | Drugs

Dasatinib 50 mg daily is as effective and less toxic than 100 mg daily for newly diagnosed CML-CP

In a post by Hagop Kantarjian on Twitter, it says, "Dasatinib 50 mg daily is…

Jun 9, 2023, 02:54 | Insight

The field of BPDCN is rapidly evolving - Hagop Kantarjian

The field of BPDCN is rapidly evolving. Our new article by Dr. Pemmaraju highlights the…

May 14, 2023, 09:40 | Positive

Legendary Dr. Hagop Kantarjian Receives Karnofsky Award for Transforming Care in Leukemia

Legendary Dr. Hagop Kantarjian Receives Karnofsky Award for Transforming Care in Leukemia Hagop Kantarjian, MD,…